iRhythm Q4 revenue rises 27.1%, beats analyst estimates

Reuters02-20

iRhythm Q4 revenue rises 27.1%, beats analyst estimates

Overview

Digital health care firm's Q4 revenue rose 27.1%, beating analyst expectations
Adjusted EPS for Q4 beat analyst expectations
Company achieved first positive GAAP net income in its history

Outlook

iRhythm expects 2026 revenue between $870 mln and $880 mln
Company anticipates 2026 adjusted EBITDA margin of 11.5% to 12.5%

Result Drivers

INCREASED DEMAND - Revenue growth driven by increased demand for Zio services and favorable pricing
OPERATIONAL EFFICIENCIES - Gross margin improvement attributed to scale and manufacturing efficiencies
INVESTMENTS FOR GROWTH - Increased operating expenses due to volume-related costs and growth investments

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue	Beat	$208.90 mln	$201.59 mln (15 Analysts)
Q4 Adjusted EPS	Beat	$0.29	$0.03 (11 Analysts)
Q4 Net Income		$5.60 mln
Q4 Gross Margin		70.90%
Q4 Gross Profit		$148.10 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for iRhythm Holdings, Inc is $220.00, about 43% above its February 18 closing price of $153.85

Press Release: ID:nGNX71TtjP

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612235903?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-20 05:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612235903","market":"us","top_or_hot":-1,"title":"iRhythm Q4 revenue rises 27.1%, beats analyst estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>iRhythm Q4 revenue rises 27.1%, beats analyst estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Digital health care firm's Q4 revenue rose 27.1%, beating analyst expectations</p></li><li><p>Adjusted EPS for Q4 beat analyst expectations</p></li><li><p>Company achieved first positive GAAP net income in its history</p></li></ul><p><span>Outlook</span></p><ul><li><p>iRhythm expects 2026 revenue between $870 mln and $880 mln</p></li><li><p>Company anticipates 2026 adjusted EBITDA margin of 11.5% to 12.5%</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>INCREASED DEMAND - Revenue growth driven by increased demand for Zio services and favorable pricing</p></li><li><p>OPERATIONAL EFFICIENCIES - Gross margin improvement attributed to scale and manufacturing efficiencies</p></li><li><p>INVESTMENTS FOR GROWTH - Increased operating expenses due to volume-related costs and growth investments</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>$208.90 mln</p></td><td><p>$201.59 mln (15 Analysts)</p></td></tr><tr><td><p>Q4 Adjusted EPS</p></td><td><p>Beat</p></td><td><p>$0.29</p></td><td><p>$0.03 (11 Analysts)</p></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>$5.60 mln</p></td><td></td></tr><tr><td><p>Q4 Gross Margin</p></td><td></td><td><p>70.90%</p></td><td></td></tr><tr><td><p>Q4 Gross Profit</p></td><td></td><td><p>$148.10 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 14 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for iRhythm Holdings, Inc is $220.00, about 43% above its February 18 closing price of $153.85</p></li></ul><p>Press Release: <span>ID:nGNX71TtjP</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>iRhythm Q4 revenue rises 27.1%, beats analyst estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\niRhythm Q4 revenue rises 27.1%, beats analyst estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-20 05:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>iRhythm Q4 revenue rises 27.1%, beats analyst estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Digital health care firm's Q4 revenue rose 27.1%, beating analyst expectations</p></li><li><p>Adjusted EPS for Q4 beat analyst expectations</p></li><li><p>Company achieved first positive GAAP net income in its history</p></li></ul><p><span>Outlook</span></p><ul><li><p>iRhythm expects 2026 revenue between $870 mln and $880 mln</p></li><li><p>Company anticipates 2026 adjusted EBITDA margin of 11.5% to 12.5%</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>INCREASED DEMAND - Revenue growth driven by increased demand for Zio services and favorable pricing</p></li><li><p>OPERATIONAL EFFICIENCIES - Gross margin improvement attributed to scale and manufacturing efficiencies</p></li><li><p>INVESTMENTS FOR GROWTH - Increased operating expenses due to volume-related costs and growth investments</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>$208.90 mln</p></td><td><p>$201.59 mln (15 Analysts)</p></td></tr><tr><td><p>Q4 Adjusted EPS</p></td><td><p>Beat</p></td><td><p>$0.29</p></td><td><p>$0.03 (11 Analysts)</p></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>$5.60 mln</p></td><td></td></tr><tr><td><p>Q4 Gross Margin</p></td><td></td><td><p>70.90%</p></td><td></td></tr><tr><td><p>Q4 Gross Profit</p></td><td></td><td><p>$148.10 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 14 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for iRhythm Holdings, Inc is $220.00, about 43% above its February 18 closing price of $153.85</p></li></ul><p>Press Release: <span>ID:nGNX71TtjP</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nL1N3ZF1BM:1","article_id":"2612235903","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612235903","pubTimestamp":1771536892,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"iRhythm Q4 revenue rises 27.1%, beats analyst estimatesOverviewDigital health care firm's Q4 revenue rose 27.1%, beating analyst expectationsAdjusted EPS for Q4 beat analyst expectationsCompany achiev","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","IRTC":"Irhythm Technologies Inc.","BK4563":"昨日强势股"},"translate_title":"iRhythm第四季度收入增长27.1%，超出分析师预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRTC":0.9},"content_text":"iRhythm Q4 revenue rises 27.1%, beats analyst estimatesOverviewDigital health care firm's Q4 revenue rose 27.1%, beating analyst expectationsAdjusted EPS for Q4 beat analyst expectationsCompany achieved first positive GAAP net income in its historyOutlookiRhythm expects 2026 revenue between $870 mln and $880 mlnCompany anticipates 2026 adjusted EBITDA margin of 11.5% to 12.5%Result DriversINCREASED DEMAND - Revenue growth driven by increased demand for Zio services and favorable pricingOPERATIONAL EFFICIENCIES - Gross margin improvement attributed to scale and manufacturing efficienciesINVESTMENTS FOR GROWTH - Increased operating expenses due to volume-related costs and growth investmentsKey DetailsMetricBeat/MissActualConsensus EstimateQ4 RevenueBeat$208.90 mln$201.59 mln (15 Analysts)Q4 Adjusted EPSBeat$0.29$0.03 (11 Analysts)Q4 Net Income$5.60 mlnQ4 Gross Margin70.90%Q4 Gross Profit$148.10 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 14 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the advanced medical equipment & technology peer group is \"buy\"Wall Street's median 12-month price target for iRhythm Holdings, Inc is $220.00, about 43% above its February 18 closing price of $153.85Press Release: ID:nGNX71TtjPFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612235903","isCrawlerRequest":true}